The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s. Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...